CNRIP1 and schizophrenia: Regulation of CB1 receptor activity by CRIP1a can be investigated at both the functional and structural levels with the goal of designing peptide or small molecule drugs that can selectively target the CRIP1a-CB1 receptor interaction for therapeutic intervention in the treatment of pain, convulsions [11,12,13,14], schizophrenia [15,16], and neurodegenerative motor disorders [17].